Could Biomarkers of Bone, Cartilage or Synovium Turnover Be Used for Relapse Prediction in Rheumatoid Arthritis Patients?
Authors:
Open Access
- 12 March 2014
- journal article
- review article
- Published by Wiley in Mediators of Inflammation
- Vol. 2014, 1-7
Abstract
Objective. The aim of this review is to clarify the usefulness of bone, cartilage, and synovial biomarker in the management of rheumatoid arthritis (RA) therapy in remission.Synovial Biomarkers. High MMP-3 levels are associated with joint progression in RA patients, but there is no data about their utility in clinical remission. IIINys and Glc-Gal-PYD seem to be more specific to synovium, but more studies are required.Cartilage Biomarkers. Unbalance between cartilage break-down biomarkers (urinary CTX II and COMP) and cartilage formation biomarker (PIIANP) was described. This unbalance is also associated with joint destruction and prognosis of destruction. No data are available on patients in remission.Bone Biomarkers. RA activity is correlated with an increase of bone resorption markers such as CTX I, PYD, and TRACP 5b and a decrease of bone formation markers such as OC and BALP. RA therapies seem to improve bone turnover in limiting bone resorption. There is no study about bone marker utility in remission.Conclusion. Biomarkers seem to correlate with RA activity and progression. They also could be used to manage RA therapies, but we need more data on RA remission to predict relapse.Keywords
This publication has 70 references indexed in Scilit:
- Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritisBMC Musculoskeletal Disorders, 2013
- Impact of Rheumatoid Arthritis Disease Activity Test on Clinical PracticePLOS ONE, 2013
- A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt studyRheumatology, 2013
- An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progressionRheumatology, 2013
- Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid ArthritisMediators of Inflammation, 2013
- Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow upArthritis Research & Therapy, 2012
- Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunitiesArthritis Research & Therapy, 2011
- Cartilage homeostasis in health and rheumatic diseasesArthritis Research & Therapy, 2009
- Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2006
- The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen DegradationJournal of Bone and Mineral Research, 2003